Table 1.

Sub-group analysis for patients with superficial or complete wound dehiscence

		Type of wound dehiscence
		Superficial dehiscence (n = 45)	Complete dehiscence (n = 9)	p-value
Age		53.80 ± 11.14	59.11 ± 4.31	p = 0.269
BMI		30.08 ± 4.89	32.04 ± 6.48	p = 0.470
Years of dialysis		5.04 ± 3.73	4.50 ± 3.64	p = 0.798
Glucose (mmol/L)		6.40 ± 1.91	6.58 ± 3.15	p = 0.588
Duration of NPWT (days)		40.50 ± 25.80	58.40 ± 36.90	p = 0.244
Time to healing (days)		45.69 ± 32.12	37.40 ± 25.81	p = 0.882
BMI	Quartile 1	9 (22.0%)	0 (0%)	p = 0.266
	Quartile 2	9 (22.0%)	3 (42.9%)
	Quartile 3	10 (24.4%)	3 (42.9%)
	Quartile 4	13 (31.7%)	1 (14.3%)
Sex	Male	30 (66.7%)	4 (44.4%)	p = 0.208
	Female	15 (33.3%)	5 (55.6%)
Type of dialysis	Predialysis	2 (4.5%)	1 (11.1%)	p = 0.238
	Haemodialysis	39 (88.6%)	6 (66.7%)
	Peritoneal dialysis	3 (6.8%)	2 (22.2%)
Smoker		10/29 (34.5%)	3/6 (50%)	p = 0.474
Diabetes mellitus		18/45 (40.0%)	4/8 (50%)	p = 0.597
Peripheral vascular disease		5/45 (11.1%)	4/9 (44.4%)	p = 0.014
Type of donor	Living	7 (15.6%)	2 (22.2%)	p = 0.855
	Brain death	29 (64.4%)	5 (55.6%)
	Cardiac death	9 (20.0%)	2 (22.2%)
Immuno-suppression	Tacrolimusa	35/45 (77.8%)	6/8 (75%)	p = 0.863
	Cyclosporinb	10/55 (22.2%)	2/8 (25%)
Delayed graft function		21/45 (46.7%)	5/9 (55.6%)	p = 0.626
Post-operative dialysis		19/45 (42.2%)	5/9 (55.6%)	p = 0.462
Infection		32/45 (71.1%)	8/9 (88.9%)	p = 0.267
Wound collection		17/45 (37.8%)	7/9 (77.8%)	p = 0.027
Operative intervention		3/45 (6.7%)	9/9 (100%)	p < 0.001
NPWT		11/45 (24.4%)	5/9 (55.6%)	p = 0.062

^aTacrolimus based regimen: basiliximab induction followed by maintenance with tacrolimus, a glucocorticoid and mycophenolate mofetil

^bCyclosporin based regimen: as above but using cyclosporin instead of tacrolimus

Bold typeface was used to distinguish significant (p<0.05) results